Top Markets
#1 Akedo Akedo +136.52%
#2 TENDIES TENDIES +87.88%
#3 Verus Coin Verus Coin +43.84%
#4 Threshold Network Threshold Network +43.74%
#5 Bitway Bitway +27.02%
#6 Mubarak Mubarak +25.52%
#7 Cash Cat Cash Cat +23.53%
#8 Palladium Network Palladium Network +22.71%
#9 MultiversX MultiversX +20.20%
#10 Wrapped Aave Ethereum USDC Wrapped Aave Ethereum USDC +18.00%
Coin of the day
Akedo Akedo
설정
언어
한국어
통화
USD
테마
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
주식 순위 #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
주가
$8.16
마지막 동기화: 2025-06-26
시가총액
$234.57M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Regulus Therapeutics Inc. (RGLS)

카테고리

Healthcare
Regulus Therapeutics Inc. (RGLS)의 매출
Mar 2025 기준 매출 TTM: $340.00K
Regulus Therapeutics Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $340.00K입니다. 2023년에 회사는 0.00의 수익을 올렸으며 이는 2022년의 0.00 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Regulus Therapeutics Inc.의 수익 기록 (2010 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $340.00K 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 -100.00%
2020 $10.01M 46.46%
2019 $6.83M 9,388.89%
2018 $72.00K 0.00%
2017 $72.00K -93.97%
2016 $1.19M -94.25%
2015 $20.76M 170.69%
2014 $7.67M -60.81%
2013 $19.57M 54.09%
2012 $12.70M -7.90%
2011 $13.79M 60.32%
2010 $8.60M 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 3,712,929.41%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 1,770,866.86%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 655,194.12%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 4,630,584.45%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH